Safety and Immunogenicity After a Three-Dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant Recipients.
Humans
CD8-Positive T-Lymphocytes
COVID-19
/ prevention & control
COVID-19 Vaccines
Graft vs Host Disease
/ epidemiology
Hematopoietic Stem Cell Transplantation
Immunization, Secondary
Interleukin-2
Prospective Studies
SARS-CoV-2
CD4-Positive T-Lymphocytes
Immunity, Humoral
Immunity, Cellular
Immunogenicity, Vaccine
Hematopoietic stem cell transplantation
SARS-CoV-2
Vaccines
Journal
Transplantation and cellular therapy
ISSN: 2666-6367
Titre abrégé: Transplant Cell Ther
Pays: United States
ID NLM: 101774629
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
06
06
2022
revised:
18
07
2022
accepted:
23
07
2022
pubmed:
2
8
2022
medline:
12
10
2022
entrez:
1
8
2022
Statut:
ppublish
Résumé
In allogeneic stem cell transplant (Allo-SCT) recipients, the cell-mediated and humoral immunogenicity of the 3-dose SARS-CoV-2 vaccination schedule has not been investigated in prospective studies. In a prospective cohort, we recruited 122 Allo-SCT recipients since August 2021, when Ontario began offering a 3-dose vaccine schedule for Allo-SCT recipients. We determined humoral and cell-mediated immunity and adverse effects of the 3-dose SARS-COV-2 vaccination schedule in Allo-SCT recipients. In immunogenicity analysis (n = 95), the median (interquartile range [IQR]) antibody titer against the receptor-binding domain (RBD) of the spike (S) protein after the third dose (10,358.0 U/mL [IQR = 673.9-31,753.0]) was significantly higher than that after the first (10.2 U/mL [IQR = 0.6-37.0]) and the second doses (125.6 U/mL [IQR = 2.8-1251.0]) (P < .0001). The haploidentical donor status was an independent risk factor (adjusted odds ratio = 7.67, 95% confidence interval [CI], 1.86-31.60) for suboptimal antibody response (anti-RBD < 100 U/mL). S-specific CD4
Identifiants
pubmed: 35914727
pii: S2666-6367(22)01510-X
doi: 10.1016/j.jtct.2022.07.024
pmc: PMC9334861
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
Interleukin-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
706.e1-706.e10Informations de copyright
Copyright © 2022. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Conflict of interest D.K. has received research grants from Roche, GSK and advisory fees from Roche, GSK, Merck, Astellas, Sanofi, Exevir. A.H. has received clinical trials grant from Merck and advisory fees from Merck. SMHM has received Quality Improvement grant from Merck and advisory fees from AstraZeneca and GSK.
Références
N Engl J Med. 2021 Dec 9;385(24):e83
pubmed: 34614327
Lancet. 2021 Dec 18;398(10318):2258-2276
pubmed: 34863358
Br J Haematol. 2022 Feb;196(4):884-891
pubmed: 34713441
Vaccines (Basel). 2021 Oct 19;9(10):
pubmed: 34696317
Transplant Cell Ther. 2021 Sep;27(9):788-794
pubmed: 34214738
J Hematol Oncol. 2021 Oct 24;14(1):174
pubmed: 34689821
Expert Rev Clin Immunol. 2019 Jul;15(7):735-751
pubmed: 31070946
EBioMedicine. 2021 Dec;74:103705
pubmed: 34861491
Lancet. 2021 May 15;397(10287):1819-1829
pubmed: 33964222
Nat Immunol. 2022 Mar;23(3):380-385
pubmed: 35115679
J Clin Microbiol. 2021 Jan 21;59(2):
pubmed: 33139419
Cancer Cell. 2021 Nov 8;39(11):1448-1449
pubmed: 34717827
Bone Marrow Transplant. 2022 Mar;57(3):502-503
pubmed: 35017662
Nat Immunol. 2022 Feb;23(2):186-193
pubmed: 35105982
Vaccines (Basel). 2022 Mar 14;10(3):
pubmed: 35335079
JAMA Netw Open. 2021 Sep 1;4(9):e2126344
pubmed: 34519770
N Engl J Med. 2021 Sep 23;385(13):1244-1246
pubmed: 34379917
J Infect Dis. 2021 Dec 1;224(11):1849-1860
pubmed: 34739078
Am J Transplant. 2021 Dec;21(12):3980-3989
pubmed: 34347934
Bone Marrow Transplant. 1995 Jun;15(6):825-8
pubmed: 7581076
Blood. 2022 Jan 6;139(1):137-142
pubmed: 34657156
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Blood. 2022 Jan 6;139(1):134-137
pubmed: 34818411
Transplant Cell Ther. 2021 Nov;27(11):938.e1-938.e6
pubmed: 34274492
Lancet Haematol. 2021 Mar;8(3):e185-e193
pubmed: 33482113
Lancet Haematol. 2021 Oct;8(10):e681-e683
pubmed: 34487683
Blood. 2010 May 13;115(19):3861-8
pubmed: 20215642
Vaccines (Basel). 2021 Sep 25;9(10):
pubmed: 34696183
Biol Blood Marrow Transplant. 2015 Mar;21(3):389-401.e1
pubmed: 25529383
Transplant Cell Ther. 2021 Sep;27(9):796.e1-796.e7
pubmed: 34256172
Transplant Cell Ther. 2021 Oct;27(10):880.e1-880.e4
pubmed: 34293520
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Clin Microbiol Infect. 2022 Feb;28(2):303.e1-303.e4
pubmed: 34715348